Europe
The Right to Try Act, signed into law by President Donald Trump last spring, may be seeing its first fruits. A California brain cancer patient who did not qualify for participation in a clinical trial will get the chance to see if an experimental glioblastoma treatment will save his life.
On Tuesday, Takeda Pharmaceutical finally wrapped up its $62 billion acquisition of Shire plc. As the combined companies continue to merge and shape their combined roles, Chief Executive Officer Christophe Weber is already eying potential deals to offset some of the debt the company garnered.
In 2015, shares of Allergan were trading at $331.15. This morning, the price of that stock is more than half that price, $145.60 following a 2.2 percent increase after the first day of the J.P. Morgan Healthcare Conference.
Galapagos NV received a transparency notification from Sands Capital Management, LLC.
Medigene AG reported today that an additional European Patent was granted for its dendritic cell (DC) vaccine platform.
FIRST PROGRAMME ADVANCED INTO LEAD OPTIMISATION
Torben Weilmuenster has been elected as Chairman of the governing council of Poseidon, the groundbreaking pharmaceutical logistics program
License allows Cell Guidance Systems to use Lightning-Link® in manufacture of TRIFic™ exome detection immunoassay kits
The Lead Discovery Center (LDC) has teamed up with McGill University in Canada, Institut National de la Santé Et de la Recherche Médicale (INSERM) in France and Semmelweis University in Hungary to discover new approaches for the treatment of alpha-1 antitrypsin deficiency (ATD), a rare genetic disorder that lead to severe lung and liver diseases.
Vectura Group plc (LSE: VEC) (“Vectura” or “the Group”) today announces an unaudited 2018 pre-close trading update. The Group expects revenue to be in line with, and EBITDA to be materially above, current market consensus expectations.
PRESS RELEASES